ZELTIQ Aesthetics, Inc. Announces Pricing of Public Offering of Common Stock
November 07 2013 - 9:06PM
ZELTIQ®, (Nasdaq:ZLTQ) a medical technology company focused on
developing and commercializing products utilizing its proprietary
controlled-cooling technology platform, announced today that it has
priced an underwritten public offering of 4,500,000 shares of its
common stock, all of which are being offered by selling
stockholders, at a price to the public of $13.00 per share. The
selling stockholders have also granted the underwriters a 30-day
option to purchase up to 675,000 additional shares. Goldman Sachs
& Co. and J.P. Morgan Securities LLC are acting as joint
book-running managers for the offering, and Canaccord Genuity Inc.
and William Blair & Company, L.L.C. are acting as co-managers
for the offering.
A registration statement relating to the offering has been filed
with the Securities and Exchange Commission (the "SEC"). A
preliminary prospectus supplement relating to the offering has
been, and a final prospectus supplement relating to the offering
will be, filed with the SEC. Copies of the preliminary prospectus
supplement and, when available, the final prospectus supplement,
relating to these securities may be obtained by visiting the SEC's
website at www.sec.gov or from Goldman Sachs & Co., Attn:
Prospectus Department, 200 West Street, New York, NY 10282, or by
calling toll-free at (866)-471-2526, or from J.P. Morgan Securities
LLC at c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, Attention: Prospectus Department, or by calling
866-803-9204.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
jurisdiction.
About ZELTIQ® Aesthetics, Inc.
ZELTIQ is a medical technology company focused on developing and
commercializing products utilizing its proprietary
controlled-cooling technology platform. ZELTIQ's first commercial
product, the CoolSculpting System, is designed to selectively
reduce stubborn fat that may not respond to diet or exercise.
CoolSculpting is based on the scientific principle that fat cells
are more sensitive to cold than the overlying skin and surrounding
tissues. It utilizes patented technology of precisely
controlled cooling to reduce the temperature of fat cells in the
treated area, which is intended to cause fat cell elimination
through a natural biological process known as apoptosis. ZELTIQ
developed CoolSculpting to safely, noticeably, and measurably
reduce the fat layer.
Cautionary Information Regarding Forward Looking
Statements
The statements in this press release regarding ZELTIQ's
intentions with respect to the public offering are forward-looking
statements that are subject to significant risks and uncertainties,
and actual results could differ materially from those projected.
These risks and uncertainties include, without limitation, risks
and uncertainties related to satisfaction of customary closing
conditions related to the public offering. There can be no
assurance that the public offering will be completed on the
anticipated terms, or at all. The forward-looking statements in
this release speak only as of this date, and ZELTIQ disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
CONTACT: Patrick F. Williams
ZELTIQ, Senior Vice President and CFO
925-474-2500
Nick Laudico / Rada Milenovici
The Ruth Group
646-536-7030 / 646-536-7011
Zeltiq Aesthetics, Inc. (NASDAQ:ZLTQ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zeltiq Aesthetics, Inc. (NASDAQ:ZLTQ)
Historical Stock Chart
From Jul 2023 to Jul 2024